• Home
  • A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.

A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.

Author List
Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA
Publication
Cancer chemotherapy and pharmacology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1474269
Publication Year
2010
PubMed ID
20130876
Publication Title
Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7.